WaKING: Wnt and checKpoint INhibition in Gastric Cancer
Status:
Recruiting
Trial end date:
2025-09-11
Target enrollment:
Participant gender:
Summary
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design
for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with
advanced unresectable or metastatic OGA who have progressed following chemotherapy.